Biotechnology & Life Sciences Investments

IKON Group Investments backs pioneering biotechnology and life sciences companies that are advancing human health through cutting-edge research, novel therapies, and scientific innovation.

Peptide Therapy & Biotechnology

Through Kynetide Peptides and Renew Lab Group, IKON has built a significant position in the rapidly growing peptide therapeutics market, valued at over $48 billion globally.

Research & Development Focus

Our life sciences portfolio companies invest heavily in R&D, leveraging proprietary formulations, bioactive compounds, and advanced delivery systems to create defensible competitive moats.

Regulatory Strategy

We partner with management teams experienced in navigating FDA, GMP, and international regulatory frameworks, ensuring compliance while accelerating time to market.

Exit Pathways

Life sciences investments offer multiple exit pathways including strategic acquisitions by major pharma companies, partnership licensing deals, and public market listings.

About IKON Group Investments: IKON Group Investments is a Houston-based global holding company managing a diversified over $1 billion portfolio across high-growth sectors worldwide. Founded by Rhett Kenagy, IKON deploys patient capital with conviction.